INTRODUCTION: Ranibizumab and aflibercept are anti- @entity7 agents licensed for the treatment of @entity227 due to macular @entity4 secondary to branch @entity2994 (BRVO). The aim of this study was to estimate, from a UK healthcare payer's perspective, the cost-effectiveness of ranibizumab versus aflibercept in this indication. METHODS: A Markov model was used to simulate the outcomes and costs of treating BRVO. @entity1 baseline characteristics and efficacy data for ranibizumab were obtained from the BRAVO trial. The relative efficacy of aflibercept was derived from a published network meta-analysis. Injection frequencies were derived from ranibizumab and aflibercept studies included in the network meta-analysis. Health states were defined by increments of 10  letters in best corrected visual acuity (BCVA). @entity1 could gain or lose a maximum of two health states between cycles. The first cycle was 6  months, followed by monthly cycles. Different utility values were assigned to the better-seeing and worse-seeing eyes based on BCVA. A 2-year treatment time frame and a lifetime time horizon were used. Future costs and health outcomes were discounted at 3.5% per annum. Sensitivity analyses were used to test the robustness of the model. RESULTS: The lifetime cost per @entity1 treated was   15,273 with ranibizumab and   17,347 with aflibercept. Ranibizumab was dominant over aflibercept, producing incremental health gains of 0.0120 quality-adjusted life-years (QALYs) and cost savings of   2074. Net monetary benefit for ranibizumab at a willingness-to-pay threshold of   20,000/QALY was   2314. Sensitivity analyses showed that the results were robust to variations in model parameters. CONCLUSIONS: Ranibizumab provides greater health gains at a lower overall cost than aflibercept in the treatment of @entity227 due to macular @entity4 secondary to BRVO. Ranibizumab is therefore cost-effective from a UK healthcare payer's perspective. FUNDING: Novartis Pharma AG, Basel, Switzerland.

Cost-Effectiveness of Ranibizumab Versus Aflibercept for Macular @entity4 Secondary to Branch XXXX : A UK Healthcare Perspective.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patient', 'Patient'] @entity227 :: ('MESH:D014786', 'Disease') :: ['visual impairment'] @entity7 :: ('7422', 'Gene') :: ['vascular endothelial growth factor'] @entity2994 :: ('MESH:D012170', 'Disease') :: ['retinal vein occlusion'] @entity4 :: ('MESH:D004487', 'Disease') :: ['edema']
@entity2994 :: (MESH:D012170,Disease) :: ['Retinal Vein Occlusion']
